FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

ington,	D.C.	20549		

5 4 , 2 44 1	OMB APPI	ROVAL
STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP	OMB Number:	3235-0287

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

OIVID APPROVAL									
3235-0287									
Estimated average burden									
0.5									

1. Name and Address of Reporting Person* ROBINS CHAD M				2. Issuer Name and Ticker or Trading Symbol Adaptive Biotechnologies Corp [ADPT]									all app Direc Office	tor er (give title	ng Pei	10% O	wner		
(Last) (First) (Middle) C/O ADAPTIVE BIOTECHNOLOGIES CORPORATION					3. Date of Earliest Transaction (Month/Day/Year) 01/19/2021								Λ	below	() CEO and	Cha	below) irman		
1551 EA	STLAKE A	VE E STE 200			4. If Amendment, Date of Original Filed (Month/Day/Year)							6. Individual or Joint/Group Filing (Check Applicable							
(Street) SEATTLE WA 98102				Line) X Form filed by One Reporting Person Form filed by More than One Reporting Person															
(City)	(St	ate) (Ž	Zip)																
	Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned																		
1. Title of Security (Instr. 3) 2. Transactic Date (Month/Day/				Execution Date,				Acquired (A) or (D) (Instr. 3, 4 a		and 5) Securit		ties cially I Following	Forn (D) o	n: Direct or Indirect nstr. 4)	7. Nature of Indirect Beneficial Ownership				
									Code	v	Amount	(A) or (D)	Price		Transa	ed ction(s) 3 and 4)			(Instr. 4)
Common Stock 01/19/20)21			S ⁽¹⁾		8,300	D	\$70.	1,76		69,880		D			
Common	Stock			01/19/20	021				S ⁽¹⁾		100	D	\$71	.14	1,7	69,780		D	
		Tal	ble II								osed of, convertib				Owne	d			
1. Title of Derivative Security (Instr. 3)	Derivative Conversion Date Execution Date, Security or Exercise (Month/Day/Year) if any		4. Transa Code 8)		of Deriv Secu Acqu (A) o Disp of (D	osed) r. 3, 4	Expira	Date Exercisable and Diration Date Onth/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Ins 3 and 4)		Der Sec (Ins	Price of ivative curity etr. 5)	9. Number derivative Securities Beneficially Owned Following Reported Transaction (Instr. 4)	y	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)		
					Code	v	(A)	(D)	Date Exerc	isable	Expiration Date	Title	Amount or Number of Shares						

Explanation of Responses:

- 1. The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 22, 2020.
- 2. The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from \$70.03 to 71.02, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.

Remarks:

/s/ Chad Robins by Eric Billings, Attorney-in-Fact

01/21/2021

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.